NCT06186479招募中3 期
Clinical Trial With Aconite Pain Oil in Oncological Patients Undergoing Chemotherapy to Prevent Chemotherapy-induced Polyneuropathy (CIPN), to Reduce Symptoms Typical of CIPN and to Improve the Quality of Life of Patients With CIPN
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 350
- 试验地点
- 2
- 主要终点
- The date of occurrence of CIPN by the principal investigator/investigator using the EORTC-QLQ-CIPN20
研究概览
简要总结
The clinical trial is planned as a prospective, multicentre, blinded, randomised, placebo-controlled, national clinical trial in Germany. The clinical trial is designed for testing the prophylactic and therapeutic effects of Aconite pain oil as compared to placebo in oncological patients receiving neurotoxic chemotherapy with taxanes and/or platinum derivatives.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A consent form, fully dated and signed by the patient and the principal investigator/investigator, is available
- •Patients with a minimum age of 18 years
- •Patients with a Karnofsky Index ≥ 70%
- •Patients with an assumed life expectancy of at least 12 months
- •Patients with solid tumours
- •Patients who are scheduled to receive unmodified chemotherapy with taxanes or platinum derivatives or their combination approved in Germany for at least 3 months (3 lunar months / 12 weeks)
- •Patients of childbearing age must provide a negative pregnancy test
排除标准
- •Participation in an interventional trial (with an investigational product) that is concurrent or occurred within 4 weeks prior to inclusion in this trial
- •Pregnant and breastfeeding patients or patients who are not using effective contraception (Pearl index < 1)
- •Patients treated with topical and/or internally administered medicinal products or cosmetics containing aconite (Aconitum napellus), camphor (Camphora), lavender essential oil (Lavandulae aetheroleum), and/or quartz within 4 weeks prior to inclusion in this trial
- •Patients with known hypersensitivity to camphor and/or any of the other ingredients of Aconite Pain Oil, as well as peanut or soy
- •Patients who are not expected to be able to comprehend the significance of the clinical trial, to demonstrate the necessary compliance, and/or to complete the patient questionnaire and patient diary in the German-language for language-related, cognitive, or other reasons
- •Patients with a planned application of chemotherapy at ≥4-week intervals
- •Patients with alcohol/drug/medication dependency
- •Patients with known genetic predispositions to polyneuropathies
- •Patients with previous or current polyneuropathy irrespective of cause
- •Patients with previous or current neurotoxic medication outside the planned chemotherapy protocol that has an impact on the primary endpoint (at the investigator´s discretion) and prior taxane and/or platinum derivative administration
- •Patients with the following known comorbidities that predispose them to CIPN:
- •inadequately substituted hypothyroidism, renal insufficiency grade 4 and above, vasculitis/collagenosis, inadequately treated diabetes mellitus
- •Patients with active and/or clinically relevant infectious diseases: HIV, Lyme disease, hepatitis B/C, herpes infections
- •Known presence of multiple myeloma or non-Hodgkin's lymphoma
- •Present neurological diseases, Alzheimer's disease, multiple sclerosis, Parkinson's disease, and other neurological diseases that make it difficult or impossible to assess the primary endpoint according to the investigator's opinion
- •Patients with metastases in the central nervous system
- •History of amputation of extremities
- •Patients with distal muscle weakness and/or atrophy
- •Skin lesions or other findings in the area of the extremities that make it impossible to use the investigational product (e.g., hand-foot syndrome)
- •Presence of any other serious acute or chronic organic or mental illness with severe impairment of the general condition that impairs or prevents regular participation in the trial
- •Use of co-analgesics such as gabapentin, pregabalin, amitriptyline, nortriptyline, clomipramine, imipramine, duloxetine 1 week before commencement of the trial (baseline) and intake during the trial before reaching CIPN grade III
- •Planned acupuncture for the treatment of CIPN during the trial
- •Topical application of substances such as lidocaine, capsaicin, botulinum toxin, amitriptyline, menthol to hands and/or feet up to 1 week before trial entry (baseline) and application during the trial
- •Electrotherapy on the extremities up to 1 week before the start of the trial (baseline) and during the trial
研究组 & 干预措施
Verum
Experimental
干预措施: Aconite pain oil (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
The date of occurrence of CIPN by the principal investigator/investigator using the EORTC-QLQ-CIPN20
时间窗: on average every 3 weeks for max. 27 weeks
Percentage of CIPN grade II and higher measured by "Common Terminology Criteria for Adverse Events" (CTC-AE v4.0 of 2010)
时间窗: on average every 3 weeks for max. 27 weeks
for neuralgia, paraesthesia, peripheral motor polyneuropathy, peripheral sensory polyneuropathy
Percentage of CIPN measured by "Common Terminology Criteria for Adverse Events" (CTC-AE v4.0 of 2010)
时间窗: on average every 3 weeks for max. 27 weeks
for neuralgia, paraesthesia, peripheral motor polyneuropathy, peripheral sensory polyneuropathy
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
招募中
2 期
Efficacy of N-acetylcysteine in Preventing Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients.Oral Mucositis (Ulcerative) Due to RadiationNCT06354712Mansoura University50
已完成
3 期
Delivra Joint Health Cream In The Treatment Of Pain Caused By Osteoarthritis Of The KneeOsteoarthritisNCT02193711Delivra, Inc.160
Unknown
3 期
Efficacy and Safety of Ultra-low Dose Methadone as Adjuvant Analgesic in Cancer Patients With PainPain, IntractableNCT02687347McGill University Health Centre/Research Institute of the McGill University Health Centre204
招募中
4 期
Correction of Anemia With Enarodustat in Non-dialysis Dependent Chronic Kidney DiseaseChronic Kidney Disease Associated AnemiaNCT06725810Shanghai Zhongshan Hospital1,670
已完成
2 期
Pretreatment Aceclofenac Effect on Pain and Analgesic Intake After Endodontic TreatmentSymptomatic Irreversible PulpitisNCT03335007Cairo University70